• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 12:45:30 PM ET
    $FLXN
    Major Pharmaceuticals
    Health Care
    Get the next $FLXN alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 6 )*

                

    Flexion Therapeutics, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    33938J106


    (CUSIP Number)

    December 31, 2020


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 33938J106

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital World Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 3,823,000
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 3,823,000
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    3,823,000 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Flexion Therapeutics, Inc.
    (b) Address of Issuer's Principal Executive Offices
    10 Mall Road, Suite 301, Burlington, MA 01803
    Item 2.
    (a) Name of Person Filing
    Capital World Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    33938J106
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    3,823,000 **
    (b) Percent of Class:
    7.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 3,823,000
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 3,823,000
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl and Capital International K.K. (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 3,823,000 shares or 7.8% of the 49,315,130 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    SMALLCAP World Fund, Inc.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital World Investors
    By: /s/ Michael J. Triessl
    Date: February 16, 2021
    Name: Michael J. Triessl
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $FLXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FLXN

    DatePrice TargetRatingAnalyst
    11/19/2021Outperform → Market Perform
    Northland Capital Markets
    10/19/2021$25.00 → $10.00Buy → Neutral
    HC Wainwright & Co.
    10/12/2021$20.00 → $12.00Outperform → Market Perform
    BMO Capital
    10/12/2021Strong Buy → Market Perform
    Raymond James
    10/12/2021$14.00 → $10.00Outperform → Neutral
    Credit Suisse
    8/6/2021$8.00 → $6.00Neutral
    Goldman Sachs
    8/5/2021$20.00 → $18.00Buy
    Needham
    More analyst ratings

    $FLXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Flexion Therapeutics downgraded by Northland Capital Markets

      Northland Capital Markets downgraded Flexion Therapeutics from Outperform to Market Perform

      11/19/21 8:56:45 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Flexion Therapeutics from Buy to Neutral and set a new price target of $10.00 from $25.00 previously

      10/19/21 6:23:51 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics downgraded by BMO Capital with a new price target

      BMO Capital downgraded Flexion Therapeutics from Outperform to Market Perform and set a new price target of $12.00 from $20.00 previously

      10/12/21 7:24:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement

      10/11/21 7:00:00 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Flexion Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Business Highlights

      ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales were $28.2 million in Q2 2021, reflecting growth of 15% over the previous quarterNet loss in Q2 2021 decreased by $10.4 million (32%), as compared to Q2 2020, during the height of the COVID-19 impact on ZILRETTA salesCompany extends estimated cash runway into 2023 by refinancing term loanFlexion reiterates full-year 2021 ZILRETTA net sales guidance in the range of $120 million to $130 millionData for FX301 bunionectomy study and FX201 single ascending dose/expansion knee osteoarthritis (OA) study anticipated by year-endConference call to be held today at 4:30 pm BURLINGTON, Mass., Aug. 04, 2021 (GLOBE NEW

      8/4/21 4:01:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics to Report Second-Quarter 2021 Financial Results on August 4, 2021

      BURLINGTON, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced that it will report its second-quarter 2021 financial results after the close of the U.S. financial markets on Wednesday, August 4, 2021 at 4:30 p.m. ET. A live webcast of the conference call can be accessed through the "Investors" tab on the Flexion Therapeutics website, and a replay will be available online after the call. For those planning to ask a question, the dial-in number for the conference call is 855-770-0022 for domestic participants and 908-982-4677 for international participants, with Conference ID # 3846257. Please dial in at least 15 minutes in advance to ensure

      7/29/21 4:15:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

      Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi

      6/15/22 8:00:00 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (NASDAQ:FLXN). "This is an exciting day for Pacira BioSciences as this acquisition expands our industry leadership and marks a major milestone in our strategy to build a robust offering of novel, non-opioid treatments to im

      11/19/21 8:40:10 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management

      -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced a definitive agreement

      10/11/21 7:00:00 AM ET
      $FLXN
      $PCRX
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $FLXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Newtyn Management, Llc

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 7:00:12 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares

      3 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/23/21 6:57:24 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes

      4 - Flexion Therapeutics Inc (0001419600) (Issuer)

      11/19/21 10:20:34 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    SEC Filings

    See more
    • SEC Form 15-12B filed by Flexion Therapeutics, Inc.

      15-12B - Flexion Therapeutics Inc (0001419600) (Filer)

      11/29/21 4:15:36 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Flexion Therapeutics, Inc.

      EFFECT - Flexion Therapeutics Inc (0001419600) (Filer)

      11/26/21 12:15:07 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Flexion Therapeutics, Inc.

      S-8 POS - Flexion Therapeutics Inc (0001419600) (Filer)

      11/19/21 9:29:02 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer

      Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced the appointment of Adam Muzikant, PhD, as Chief Business Officer. Dr. Muzikant brings 18 years of business development experience creating and executing value-creating deals, from platform collaborations to commercial-stage product licenses and M&A, across a range of therapeutic areas and technologies at both private and public biopharmaceutical companies. In his role at Avilar, Dr. Muzikant will be responsible for corporate and business development as well as various business operations functions. This press release features multimedia. View the full release here: https://www.busi

      6/15/22 8:00:00 AM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics Announces Appointment of Utpal Koppikar to its Board of Directors

      BURLINGTON, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ:FLXN) today announced the appointment of Utpal Koppikar, Chief Financial Officer of Atara Biotherapeutics, to its Board of Directors. Mr. Koppikar will serve as the chair of Flexion's audit committee. "I am thrilled to welcome Utpal to Flexion's Board, as his extensive financial experience leading biotechnology companies makes him an outstanding addition to our Board of Directors," said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. "In addition to Utpal's anticipated contributions guiding our corporate strategy, I look forward to his stewardship and counsel as chai

      7/12/21 4:30:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • Flexion Therapeutics Announces Appointment of William T. Andrews, M.D., F.A.C.P., as Chief Medical Officer

      BURLINGTON, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that William T. Andrews, M.D., F.A.C.P., will join the company as Chief Medical Officer (CMO), effective July 1, 2021. "Will brings an impressive combination of medical, clinical, regulatory and corporate development skills, complemented by deep commercial experience he gained launching seven products throughout his career,” said Michael Clayman, MD, President and Chief Executive Officer of Flexion Therapeutics. “He will play an integral role in building and strengthening our organization, and we could not be more excited to welcome him to our senior management team.” "I have be

      6/9/21 4:15:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care

    $FLXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Flexion Therapeutics, Inc. (Amendment)

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      11/9/21 3:34:00 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Flexion Therapeutics, Inc. (Amendment)

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      5/10/21 2:23:01 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Flexion Therapeutics Inc (0001419600) (Subject)

      2/16/21 12:45:30 PM ET
      $FLXN
      Major Pharmaceuticals
      Health Care